Oncology & Cancer

Finally, a potential new approach against KRAS-driven lung cancer

The previous decade has seen dramatic advances in the treatment of non-small cell lung cancer, as genes driving subtypes of the disease including EGFR, ALK, ROS1 and BRAF are paired with drugs that silence their action. However, ...

Oncology & Cancer

Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia

Clinical trials at University of Colorado Cancer Center and elsewhere now result in the drug ivosidenib earning approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or ...

Oncology & Cancer

Blood cancer precursor found in 9/11 firefighters

A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead ...

Oncology & Cancer

Immune therapy scores big win against lung cancer in study

For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had much ...

Oncology & Cancer

Immunotherapy—cancer's new frontier

Your immune system never sleeps. Every moment of the day, immune cells monitor your body for disease, calling for backup when they detect a threat. It's a system that works elegantly—most of the time. It's not foolproof; ...

page 15 from 40